Document:

<PAGE>   1
                                                                    EXHIBIT 10.2

                        SETTLEMENT AND RELEASE AGREEMENT

         THIS SETTLEMENT AND RELEASE AGREEMENT (the "Agreement") is made and
entered into as of April 18, 2001, by and among PerkinElmer, Inc., a
Massachusetts corporation, ("PerkinElmer") and each of the members of the Board
of Directors of Genomic Solutions Inc., a Delaware corporation (the
"Corporation"), Jeffrey S. Williams, Robert G. Shepler, J. Matthew Mackowski,
Daniel J. Mitchell, Dr. Damion E. Wicker and P. Nicholas King (collectively, the
"Directors").

                                    RECITALS

         A. PerkinElmer has asserted claims against the Corporation and the
Directors in the lawsuit captioned Civil Action No. 18671 filed in the Court of
Chancery in the State of Delaware on February 12, 2001 (the "Lawsuit").

         B. Simultaneously with the execution and delivery of this Agreement,
PerkinElmer and the Corporation are entering into a settlement, release and
stock purchase agreement (the "Settlement Agreement") whereby PerkinElmer and
the Corporation intend to, and do, fully resolve, settle, and compromise the
Lawsuit and any and all claims, suits, actions or demands that PerkinElmer may
have against the Corporation or any of the members of the Board of Directors of
the Corporation and that the Corporation may have against PerkinElmer as of the
date of this Agreement.

         C. By this Agreement, PerkinElmer and each of the Directors intend to,
and do, fully resolve, settle, and compromise the Lawsuit and any and all
claims, suits, actions or demands that PerkinElmer may have against the
Directors and that the Directors may have against PerkinElmer as of the date of
this Agreement.

                            COVENANTS AND AGREEMENTS

         NOW, THEREFORE, in reliance on the respective representations and
warranties set forth below and for and in consideration of the foregoing
Recitals, the mutual covenants and agreements set forth below and other good and
valuable consideration, the receipt and adequacy of which are acknowledged,
PerkinElmer and each of the Directors, severally and not jointly, agree as
follows:

1.       RELEASES.

         (a)      PerkinElmer and its successors, assigns and legal
                  representatives, hereby waive, release, discharge, settle and
                  acquit the Directors and their agents (collectively, the
                  "Director Affiliated Parties") from any debts, claims,
                  demands, causes of action, controversies, promises, agreements
                  or obligations of any kind, type or description whatsoever,
                  including the Lawsuit, which PerkinElmer has had, now has or
                  may in the future have as to the Director Affiliated Parties
                  as the result of each, any or all claims of any kind, type or
                  nature whatsoever, liquidated or

<PAGE>   2

                  unliquidated, mature or not matured, known, unknown or
                  unknowable which PerkinElmer has had, now has or may in the
                  future have against the Director Affiliated Parties as a
                  result of or relating directly or indirectly to any matter,
                  act, omission, transaction or occurrence occurring on or prior
                  to the date of this Agreement.

         (b)      Each of the Directors and their successors, assigns and legal
                  representatives, hereby waive, release, discharge, settle and
                  acquit PerkinElmer and its officers, directors, employees and
                  agents (collectively, and together with PerkinElmer, the
                  "PerkinElmer Affiliated Parties") from any debts, claims,
                  demands, causes of action, controversies, promises, agreements
                  or obligations of any kind, type or description whatsoever,
                  which the Directors have had, now have or may in the future
                  have as to the PerkinElmer Affiliated Parties as the result of
                  each, any or all claims of any kind, type or nature
                  whatsoever, liquidated or unliquidated, mature or not matured,
                  known, unknown or unknowable which the Directors have had, now
                  have or may in the future have against PerkinElmer as a result
                  of or relating directly or indirectly to any matter, act,
                  omission, transaction or occurrence occurring on or prior to
                  the date of this Agreement.

         (c)      It is the intent of PerkinElmer and the Directors to make a
                  general release in favor of each other, except for the
                  enforcement of this Agreement, the Settlement Agreement and
                  for those agreements referenced in Section 7(a)-(d) of the
                  Settlement Agreement. Nothing contained herein shall be deemed
                  to limit the generality of the releases contained herein. It
                  is expressly understood and agreed to that it is the intent of
                  the Directors and PerkinElmer to enter into a full, complete
                  and mutual release.

2.       MISCELLANEOUS PROVISIONS.

         (a)      The rights and remedies provided for in this Agreement to
                  ensure compliance with the terms and conditions of this
                  Agreement shall be cumulative, and shall be in addition to all
                  rights and remedies otherwise available to the parties to
                  ensure compliance with the terms and conditions of this
                  Agreement, whether such rights and remedies are provided for
                  under this Agreement, any other agreement or applicable law.

         (b)      Any notice, demand, request or other communication which is
                  permitted, required or desired to be given in connection with
                  this Agreement must be in writing and shall be deemed to be
                  duly given when (i) personally delivered, (ii) deposited in
                  the United States mail, certified or registered, return
                  receipt requested, postage prepaid, addressed to the parties
                  at the following addresses (or at such other address as shall
                  be given in writing to the parties to this Agreement or their
                  permitted successors or assigns), or (iii) faxed to the
                  parties at the following fax numbers (or at such other fax
                  numbers as shall be given in writing to the parties to this
                  Agreement or their permitted successors or assigns), with a
                  hard copy to follow in the manner contemplated in either
                  clause (i) or (ii) above, as follows:

                                       2

<PAGE>   3

                           Directors:

                           See Exhibit A attached hereto

                           With a copy to:

                           Jaffe, Raitt, Heuer & Weiss, P.C.
                           One Woodward Avenue, Suite 2400
                           Detroit, MI  48226-3412
                           Fax:  (313) 961-8358
                           Attention:  Peter Sugar, Esq.

                           If to PerkinElmer:

                           PerkinElmer, Inc.
                           45 William Street
                           Wellesley, MA  02481
                           Fax:  (781) 431-4115
                           Attention: Terrance Carlson

                           With a copy to:

                           Hale and Dorr LLP
                           60 State Street
                           Boston, MA  02109
                           Fax:  (617) 526-5000
                           Attention: Kenneth Hoxsie, Esq.

         (c)      No waiver of any breach of any agreement or provision in this
                  Agreement shall be deemed a waiver of any preceding or
                  succeeding breach of this Agreement or of any other agreement
                  or provision contained in this Agreement. No extension of time
                  for performance of any obligation or act shall be deemed an
                  extension of time for performance of any other obligation or
                  act.

         (d)      This Agreement shall be binding upon and inure to the benefit
                  of the parties to this Agreement and their respective heirs,
                  representatives, successors and permitted assigns.

         (e)      If any party commences an action against any other party to
                  enforce any of the terms, covenants, conditions or provisions
                  of this Agreement, the prevailing party in any such action
                  shall be entitled to recover his or its reasonable attorneys'
                  fees,

                                       3

<PAGE>   4

                  costs and expenses incurred in connection with the prosecution
                  or defense of such action from the losing party.

         (g)      This Agreement shall be governed by and construed in
                  accordance with the internal laws of the State of Delaware
                  without regard to conflicts of law principles thereof. Each of
                  the parties hereto (i) consents to submit itself to the
                  personal jurisdiction of any federal court located in the
                  State of Delaware or any Delaware state court in the event any
                  dispute arises out of this Agreement, (ii) agrees that it will
                  not attempt to deny or defeat such personal jurisdiction by
                  motion or other request for leave from any such court and
                  (iii) agrees that it will not bring any action relating to
                  this Agreement in any court other than a federal court sitting
                  in the State of Delaware or a Delaware state court.

         (h)      The language used in this Agreement will be deemed to be the
                  language chosen by the parties hereto to express their intent,
                  and no rule of strict construction shall be applied against
                  any party. Any reference to any federal, state, local, or
                  foreign statute or law shall be deemed also to refer to all
                  rules and regulations promulgated thereunder, unless the
                  context otherwise requires.

         (i)      This Agreement may be executed in one or more counterparts,
                  each of which will be deemed an original, but all of which
                  together will constitute one and the same instrument. Copies
                  (photostatic, facsimile or otherwise) of signatures to this
                  Agreement shall be deemed to be originals and may be relied on
                  to the same extent as the originals.

         (j)      The headings in this Agreement are for reference purposes only
                  and will not in any way affect the meaning or interpretation
                  of this Agreement.

         (k)      Each party to this Agreement shall be responsible for any
                  expenses incurred by it in connection with the negotiation and
                  performance of this Agreement, including legal and accounting
                  fees.

         (l)      PerkinElmer shall promptly execute and file with the Chancery
                  Court all necessary documents to dismiss the Lawsuit with
                  prejudice and without costs to either PerkinElmer, the
                  Directors or the Corporation.

         (m)      Both PerkinElmer and each of the Directors have the full legal
                  right, power and authority to enter into this Agreement, and
                  this Agreement is a valid and binding obligation of
                  PerkinElmer and each of the Directors enforceable in
                  accordance with its terms.

                                       4

<PAGE>   5

         IN WITNESS WHEREOF, the parties have executed this Settlement and
Release Agreement as of the date first written above.

                                 PERKINELMER, INC.

                                 By:      /s/ Terrance Carlson
                                          ------------------------------------
                                          Terrance Carlson
                                 Its:     Senior Vice President
                                          ------------------------------------

                                 DIRECTORS

                                 /s/ Jeffrey S. Williams
                                 ---------------------------------------------
                                 Jeffrey S. Williams

                                 /s/ Robert G. Shepler
                                 ---------------------------------------------
                                 Robert G. Shepler

                                 /s/ J. Matthew Mackowski
                                 ---------------------------------------------
                                 J. Matthew Mackowski

                                 /s/ Daniel J. Mitchell
                                 ---------------------------------------------
                                 Daniel J. Mitchell

                                 /s/ Dr. Damion E. Wicker
                                 ---------------------------------------------
                                 Dr. Damion E. Wicker

                                 /s/ P. Nicholas King
                                 ---------------------------------------------
                                 P. Nicholas King

                                       5

<PAGE>   6

                                    Exhibit A

Jeffrey S. Williams                         Genomic Solutions Inc.
                                            4355 Varsity Drive Suite E
                                            Ann Arbor MI 48108
                                            734.975.4808 fax

Robert G. Shepler                           Mackowski & Shepler
                                            275 Post Street Suite 600
                                            San Francisco CA 94108-5005
                                            415.765.6983 fax

J. Matthew Mackowski                        Mackowski & Shepler
                                            275 Post Street Suite 600
                                            San Francisco CA 94108-5005
                                            415.765.6983 fax

Daniel J. Mitchell                          Sequel Venture Partners
                                            4430 Arapahoe Suite 220
                                            Boulder CO 80303
                                            303.546.9728 fax

Dr. Damion Wicker                           JP Morgan Partners
                                            380 Madison Ave 12th Floor
                                            New York NY 10017
                                            212.622.3755 fax

P. Nicholas King                            Homestead, 2 Church Rd
                                            Glatton Huntingdon
                                            Cambridgeshire PE17 5RR
                                            United Kingdom
                                            44.1487.830838 fax

                                       6<PAGE>   1
                                                                    EXHIBIT 10.3

         FIRST AMENDMENT TO SALES, MARKETING AND DISTRIBUTION AGREEMENT

         This First Amendment to Sales, Marketing and Distribution Agreement
("Amendment") is made as of this 18th day of April, 2001, by and between Genomic
Solutions Inc., a Delaware corporation and PerkinElmer, Inc., a Massachusetts
corporation.

         The following facts underlie this Amendment:

         Pursuant to a certain Sales, Marketing and Distribution Agreement dated
         December 14, 1999 (the "Agreement"), Genomic Solutions Inc. appointed
         PerkinElmer, Inc. as it representative to promote, market and
         distribute its products. The parties desire to amend the Agreement
         pursuant to the terms and conditions of this Amendment.

         NOW, THEREFORE, in consideration of the mutual covenants and
undertakings set forth herein and in the Agreement, the parties agree as
follows:

         1. DEFINITIONS. All capitalized terms not defined in this Amendment
shall have the meaning set forth in the Agreement. In addition, the Agreement is
amended to add the following new or substitute defined terms, as applicable:

         (a)  "Amendment Effective Date" means April 18, 2001

         (b)  "Core Markets" means the United States of America and Japan (the
              definition of Core Markets in Section 1(c) of the Agreement is
              superceded and replaced in its entirety by the foregoing
              definition).

         (c)  "GeneMAP Arrays" means the preprinted DNA microarrays developed
              and manufactured by GSI for distribution to third parties under
              the GeneMAP trademark, including both cDNA and
              oligonucleotide-based microarrays but excluding custom microarrays
              developed for third parties.

         (d)  "High Demand MicroArrays" means GSI's preprinted microarrays that
              have a quarterly sales volume of at least **** (*)microarrays of a
              particular type as evidenced by a single part number

         (e)  "MICROMAX Array" means the preprinted DNA microarrays developed
              and manufactured by PKI or its affiliates for distribution to
              third parties under the MICROMAX trademark.

----------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

<PAGE>   2

         (f)  "ProXPRESS Imager" shall mean the ProXPRESS proteomic imaging
              system manufactured by PKI and associated reagents and competitive
              fluorescent dyes as branded and private label pursuant to this
              Agreement. In the event that during the Term, PKI offers any
              modified, upgraded or replacement ProXPRESS Imager, such product
              shall automatically be deemed a "ProXPRESS Imager".

         2. TERM. Section 1(g), "Term", is amended to provide that the initial
            Term of the Agreement shall expire on December 31, 2002. Thereafter,
            the Agreement shall automatically renew for successive two (2) year
            periods unless either party notifies the other in writing at least
            ninety (90) days prior to the expiration of the initial term or the
            then current renewal period, as the case may be,of its intention not
            to renew.

         3. TRANSFER PRICING. Exhibit A and Exhibit C of the Agreement are
            hereby superceded in their entirety and replaced by Exhibit A and
            Exhibit B-1 attached. In addition, Section 3(b) and 3(c) of the
            Agreement are superceded and replaced in their entirety as follows:

         (b)  Purchase Order Quotas and Goals. GSI shall make GSI Products
              available to PKI in accordance with the terms in Section 7 and the
              transfer pricing in Exhibit A . Exhibit B-1 is a schedule of PKI
              purchase order targets for the last three quarters of 2001. These
              minimum purchase order targets are U.S. dollar volumes based on
              GSI Product orders received by GSI from PKI on or before the last
              day of the calendar quarter and are based on GSI's transfer price
              to PKI for such GSI Products. Purchase orders for GSI Products in
              excess of the minimum purchase order targets set forth on Exhibit
              B-1 for any calendar quarter shall be credited toward the minimum
              purchase order target set forth therein for subsequent calendar
              quarters. Exhibit B-1 shall be reviewed and updated annually by
              the parties on or before November 15 of each year to set new
              quarterly minimum sales targets. In the event that the parties are
              unable to agree on purchase order targets, the matter will be
              submitted for arbitration before a single arbitrator approved by
              the parties. All arbitration shall take place in accordance with
              the rules of the American Arbitration Association at such
              organizations Wilmington, Delaware offices. Such arbitrator shall
              make such adjustments based on then current market conditions.

         (c)  Failure to Meet Minimum Purchase Order Requirements. In the event
              that PKI fails to meet the quarterly minimum purchase order
              requirements for GSI Products for **** (*)GSI, in its sole
              discretion and upon notice to PKI, may

----------

(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       2
<PAGE>   3

              convert PKI's right to sell, market, distribute and provide field
              services for GSI Products outside of Core Markets from exclusive
              to non-exclusive.

         4. PROXPRESS IMAGER. The Agreement is amended to add a new Section 4A
            regarding GSI's right to distribute PKI's ProXPRESS Imager in Core
            Markets as provided in Exhibit C attached.

         5. PRODUCT COMPATIBILITY AND INFORMATION EXCHANGE

         (a)  Under no circumstances shall the manufacture and/or distribution
              of MICROMAX Arrays by PKI be considered a violation of Section
              6(b) of the Agreement. GSI and PKI will work together to ensure
              that the MICROMAX Arrays are capable of being used in conjunction
              with present and future hybridization stations and nucleic acid
              array readers manufactured by GSI, provided, that all MICROMAX
              Arrays are on 1" x 3" slides unless otherwise agreed to by GSI.

         (b)  GSI and PKI will work together to ensure that the GeneMAP Arrays
              are capable of being used in conjunction with present and future
              PKI labeling and detection technologies.

         (c)  GSI and PKI agree to meet not less frequently than once per
              calendar quarter to:

                     (i)    discuss new product ideas and developments and, in
                            the case of microarrays, to discuss possible
                            collaborations and which party will develop
                            particular array types and designs, provided, that
                            no exclusive relationship is created for either
                            party on such new ideas and developments unless the
                            parties subsequently agree otherwise;
                     (ii)   address distribution and licensing of such GSI
                            Products by PKI or the ProXPRESS Imager by GSI, as
                            the case may be, and the terms and conditions with
                            respect to such distribution or licensing to avoid
                            or minimize duplication of effort and to accelerate
                            product development and sales;
                     (iii)  to discuss future product release plans and time
                            tables (in this regard GSI will use good faith
                            efforts to give PKI sufficient lead time to prepare
                            and train for new product launches); and
                     (iv)   to discuss PKI marketing and sales efforts and
                            strategies for GSI Products (in this regard, PKI
                            will use good faith efforts to give GSI detailed
                            marketing plans on a regional and, where reasonable,
                            a country by country basis and GSI and PKI will work
                            together cooperatively to develop strategies to
                            maximize sales in such regions or countries).

                                       3
<PAGE>   4

         (d)      PKI will maintain an inventory of at least ****(*) High
                  Demand MicroArrays of a given part number commencing at such
                  time as it sells **** microarrays of such part number. GSI
                  will use commercially reasonable efforts to deliver
                  microarrays to PKI within 30 days after receipt of a purchase
                  order. Subject to Section 7 of the Agreement, GSI warrants
                  that microarrays will meet published specifications and be
                  free from defects in manufacture and workmanship for a period
                  of 90 days after shipment to PKI. GSI's obligation with
                  respect to this warranty is limited to the repair and
                  replacement of defective products after GSI's inspection and
                  verification of defects.

         (e)      GSI RESEARCH SERVICES. PKI will provide Leads to GSI for GSI's
                  research services, including custom arraying, labeling,
                  hybridization and analysis services and proteomic services.
                  For sales of research services directly attributable to Leads
                  provided by PKI, GSI shall pay to PKI a commission based on
                  the following (herein "Service Revenue"): GSI's gross revenue
                  received from the performance of such services, less tariffs,
                  taxes and similar charges and net of all discounts, returns
                  and allowances provided, that commissions shall only be
                  payable for ****. All payments shall be in the manner
                  provided in and subject to Section 4(b) of the Agreement. No
                  commissions shall be payable on purchases of services by
                  existing clients of GSI. The commission rate payable pursuant
                  to this Section shall be **** percent of the Service Revenue
                  attributable to PKI Leads.

         6.       GENEMAP ARRAYS DISTRIBUTION.

         (a) Distribution Rights. PKI shall have the exclusive right and
responsibility, commencing upon the Amendment Effective Date, to engage in
sales, marketing, distribution and field service activities with respect to
GeneMAP Arrays in any geographical area other than the Core Markets. In
addition, PKI shall have the non-exclusive right and responsibility, commencing
upon the Amendment Effective Date, to engage in sales, marketing, distribution
and field service activities with respect to GeneMAP Arrays in the Core Markets.

         (b) Pricing and Fees. Transfer pricing for GeneMap Arrays shall be as
provided on Exhibit A. PKI may sell the GeneMAP Arrays at such prices and on
such terms and conditions as it deems appropriate in its sole discretion.

         (c) GSI shall be solely responsible for any **** in connection with
the sale of GeneMAP Arrays to third parties, including, but not limited to,
**** and will indemnify and hold PKI harmless against any infringement claims
raised by third parties as provided in Section 8 of the Agreement.

----------

(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       4
<PAGE>   5

         7.   COMPETITIVE PRODUCTS.  Notwithstanding anything to the contrary in
 the Agreement:

         (a)  PKI shall be permitted to engage in the sale and distribution of
              mass spectrometry equipment, provided, that "mass spectrometry
              equipment" shall not include any equipment which competes with
              GSI's ProGest, ProPrep. ProMS and any successor products.

         (b)  GSI shall be permitted to allow **** (*)to distribute GSI's ****
              and related software and equipment on a private label or OEM basis
              notwithstanding that such activities may otherwise violate PKI's
              exclusive distribution rights, provided, that the **** is sold by
              **** as part of a system or package with other equipment and not
              on a stand-alone basis.

         (c) GSI may contract to develop or manufacture products for third
            parties provided that such products are not offered for sale by GSI
            directly.

         8.   AMENDMENT TO FULFILLMENT TERMS

         (a)  In connection with GSI's distribution of ProXPRESS Imagers
              pursuant to Section 4A as provided on Exhibit C, Sections 7 (as
              modified below) and 8 of the Agreement shall apply except that for
              purposes of ProXPRESS Imager distribution all references to "PKI"
              shall be deemed references to "GSI", all references to "GSI" shall
              be deemed references to "PKI" and all references to "GSI Products"
              shall be deemed references to "ProXPRESS Imagers" in such
              sections.

         (b)  Section 7(a) of the Agreement is replaced with the following:

              Order Placement. Orders for equipment or products other than
              reagents, gels, and consumables shall be submitted at least 45 but
              no more than 75 days prior to the expected shipment date. Orders
              for reagents, consumables and gels shall be submitted at least 30
              but no more than 60 days prior to the expected shipment date. All
              orders for consumables, reagents and gels shall be for complete
              lots, the size of which shall be determined by GNSL according to
              its normal manufacturing practices. All orders shall be bona fide,
              non-cancelable and properly addressed. The manufacturer may ship
              product upon the receipt of any order to the designated address
              (eg. no delayed shipment date).

----------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       5
<PAGE>   6

         (c)  Section 7(c) of the Agreement is replaced with the following:

              Servicing and Certain Revenue. PKI shall be solely responsible for
              all installation, field servicing, maintenance and warranty repair
              with respect to GSI Products distributed by PKI. GSI shall be
              solely responsible for all installation, field servicing,
              maintenance and warranty repair with respect to ProXPRESS Imagers
              distributed by GSI. Each party shall provide reasonable
              application and production assistance and technical support to the
              other at a rate of ****(*). Expenses shall not exceed $1000.00
              without the prior consent of the other party. Each party shall be
              entitled to receive all revenue generated from field servicing and
              maintenance. Revenue from software upgrades and software
              maintenance or subscription services shall be split equally
              between GSI and PKI.

         (d)  The Agreement is amended to add a new Section 7(l) as follows:

              International Compliance. In the event that a party distributes
              the product of the other party in a country outside of the United
              States, the distributing party will comply with all foreign laws,
              regulations and registration requirements of such country, unless
              the manufacturer or the product is already selling product
              directly into the country, in which case the manufacturer shall be
              responsible for foreign regulatory compliance of such product in
              such country.

         (e)  The Agreement is amended to add a new Section 7(m) as follows:

              Training. PKI will commit to achieve a minimum level of training
              for all relevant Life Sciences sales personnel. Such training
              level shall be agreed to between the parties within ninety (90)
              days after the Amendment Effective Date. GSI will provide the
              training to PKI sales personnel at such times and locations and
              upon such terms as may be agreed to between the parties from time
              to time.

         9.   SALE OF CYANINE NUCLEOTIDES. PKI will sell to GSI cyanine
nucleotides and TSA reagents at **** of the PKI then-current US list price,
provided that such products shall be used for GSI research purposes and research
services and shall not be used or otherwise resold to third parties. Such
products shall be shipped based on quantities set forth in GSI purchase orders
for such products. PKI shall invoice GSI for shipped product which invoices
shall be due and payable in full, in U.S. dollars, within thirty (30) days of
the invoice date.

----------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       6
<PAGE>   7

     10.      UNITED KINGDOM DISTRIBUTION AND SALES OPERATION.

         (a)  Distribution Rights and Transition.

              (i) UK Distribution Rights. The parties acknowledge that as a
result of the change in the definition of Core Markets, commencing on the
Amendment Effective Date, PKI shall have the exclusive right to market, sell,
distribute, support and service GSI Products in the United Kingdom. GSI Sales
Employees (as defined in Section 10(d)(i) below) shall undertake such sales on
behalf of PKI during the 120 day period following the Amendment Effective Date.

               (ii) Existing Orders. GSI shall be entitled to all revenue
from orders for GSI Products in the United Kingdom that are received before the
Amendment Effective Date. All such ordered GSI Products shall be shipped to the
customer or end user within 120 days of the Amendment Effective Date.

               (iii) Orders in Process. Exhibit D contains a list of all
potential clients who have received a demonstration of GSI Products, who have
been previously been identified as a key prospect or potential purchaser of GSI
Products or who have been contacted by GSI ("Existing Prospects"). GSI shall be
entitled to all revenue from orders for GSI Products from Existing Prospects
that are received within 120 days after the Amendment Effective Date. GSI shall
be responsible for all sales commission and travel, demonstration or other
expenses associated with procuring orders from Existing Prospects. All orders
for GSI Products from Existing Prospects shall be shipped within **** (*)days of
the receipt of the order by GSI.

               (iv) Other UK Sales. Except as provided in Sections 10(a)(ii)
and (iii) above, PKI shall be entitled to all revenue from sales of GSI Products
in the United Kingdom after the Amendment Effective Date (subject to payment to
GSI of the product pricing for such GSI Products).

         (b) Distribution Fee. In exchange for the grant of United Kingdom
distribution rights, PKI will pay , a distribution access fee of ****(*), which
payment shall be made by way of a credit against amounts payable by GSI to PKI
under the Settlement, Release and Stock Purchase Agreement between the parties
of even date herewith.

         (c) GSI United Kingdom Sales Personnel.

----------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       7
<PAGE>   8

                  (i) Transfer of Sales Personnel. In connection with the
         transfer of the UK Assets to PKI and effective as of the date 120 days
         after the Amendment Effective Date (the "Hire Date"), GSI shall
         terminate, and PKI shall offer employment toall current employees of
         GSI in the United Kingdom engaged primarily in the sale, service or
         support of GSI Products as listed on Exhibit E attached (the "Sales
         Employees"). The Sales Employees shall exclude those employees involved
         in order processing, product development and product management. The
         Sales Employees shall be given offers of employment by PKI at a salary
         or wage no less than that paid by GSI. GSI shall be responsible for all
         compensation, commission and benefits payable to the Sales Employees
         from the Amendment Effective Date through the Hire Date. From the
         Amendment Effective Date through the Hire Date, the Sales Employees
         shall be engaged exclusively in sales, service and support of GSI
         Products in the United Kingdom.

               (ii) Sales Efforts. During the period from the Amendment
         Effective Date through the Hire Date, the Sales Employees shall use
         their best efforts to consummate sales to Existing Prospects as well as
         new potential purchasers of the GSI Products as quickly as possible.
         PKI will not instruct or induce Sales Employees to delay sales efforts
         to Existing Prospects in order to increase PKI revenue from the United
         Kingdom.

         11.   EFFECTS OF AMENDMENT.  Except as provided in this Amendment, all
         terms and conditions of the Agreement shall remain in full force and
         effect without modification.

         IN WITNESS WHEREOF, GSI and PKI have executed this Amendment as of the
date first above written.

WITNESS:                                GENOMIC SOLUTIONS INC.

Gary A. Kendra                          By:  Jeffrey S. Williams
----------------------------              ---------------------------------

                                        Its: President and CEO
                                            -------------------------------

                                                     "GSI"

                                        PERKINELMER, INC.

John  Healy                             By:  Terrance Carlson
----------------------------               --------------------------------

                                        Its: Senior Vice President
                                            -------------------------------

                                                     "PKI"

                                       8
<PAGE>   9

                                    EXHIBIT A
                          PRODUCTS AND TRANSFER PRICING
<TABLE>
<CAPTION>
     PRODUCT                                TRANSFER PRICE
     -------                                --------------
<S>                                         <C>
Genomic Products

G3 w/32-pin (G3S2000)                         ****(*)
G3 w/48-pin (G3S2001)                         ****
G3 w/32-pin (G3A2000)                         ****
G3 w/48-pin (G3A2001)                         ****
RAI Benchtop Arrayer                          ****
Hybridization Station                         ****
UC-4 Scanner                                  ****
GeneTAC 2000 (2c)                             ****
GeneTAC LS-IV (4c)*                           ****
GeneTAC LS-IV (2c)**                          ****
4-day Biochip Training Course                 ****
2-day Biochip Training Course                 ****

Proteomic Products

Investigator 2-D                              ****
ProImage                                      ****
ProPic                                        ****
ProGest                                       ****
ProMS                                         ****
ProPrep - 4 plate                             ****
ProPrep - 8 plate                             ****
Pre-cast gel rigs (ESPCG)                     ****
3-day Proteomics Training Course              ****
1-day Proteomics Training Course              ****
</TABLE>

     GeneMap Microarrays for distribution in Core Markets: ****discount from
        U.S. List Price

     GeneMap Microarrays for distribution outside of Core Markets: ****discount
        from U.S. list price

     All  other reagents and consumables: ****discount from U.S. list price

     * Increased to ****at such time that the UC-4 Scanner is commercially
        available

     ** Increased to ****at such time that the UC-4 Scanner is commercially
        available
---------------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       9

<PAGE>   10

                                   EXHIBIT B-1

                      PKI MINIMUM QUARTERLY PURCHASE ORDERS

<TABLE>
<CAPTION>
Calendar Quarter                    Minimum Purchase Orders
---------                           -----------------------
<S>                                 <C>
Q2, 2001                            ****(*)
Q3, 2001                            ****
Q4, 2001                            ****

2002                                To be mutually agreed to
                                    between the parties no
                                    later than November 15,
                                    2001
</TABLE>
-------------------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       10

<PAGE>   11

                                    EXHIBIT C
                           NEW SECTION 4A OF AGREEMENT

4A       ProXPRESS Imagers

(a)      Appointment as Distributor. PKI hereby appoints GSI as a non-exclusive
         distributor of the ProXPRESS Imager in the Core Markets during the
         Term. PKI may sell the ProXPRESS Imager in core markets. Pursuant to
         such appointment, GSI shall be permitted to distribute, sell, market
         and provide field service with respect to the ProExprss Imagerdirectly
         to end users and through its Affiliates, distributors, value added
         resellers and dealers. . PKI shall provide at least thirty (30) days
         advance written notice of any material modification or improvement of
         the ProXPRESS Imager.

(b)      Transfer Pricing. PKI shall sell the ProXPRESS Imager to GSI at a
         transfer price of ****(*) per unit for imaging systems and a ****
         discount from list price for reagents and dyes for the balance of the
         2001 calendar year. The parties will meet and agree on transfer pricing
         for the next subsequent year of the Term on or before November 15 of
         each year of the Term, commencing on November 15, 2001.

-------------------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       11
<PAGE>   12

                                    EXHIBIT D

                              EXISTING PROSPECTS(*)

--------------------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       12
<PAGE>   13

                                    EXHIBIT E

                                SALES EMPLOYEES(*)

------------------
(*) ****Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested for the omitted
portion.

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]